Cyxtera Results Presentation Deck

Transaction Adjusted EBITDA Bridge: Q3 2021 to Q3 2022 ($ in Millions) Cyxtera (1) (2) $58.1 Q3'21 + $9.5 Change in Revenue -$6.8 Change in Cost of Revenue (2) -$8.6 Change in SG&A +$6.4 Change in Adjustments (1)(2) $58.5 Q3'22 Includes pro forma EBITDA adjustments related to one-time stand-up costs, recurring expenses, restructuring & cost-savings initiatives, as well as product development & start-up costs Excludes $1.3M in restructuring, impairment, site closures and related cost in Q3 22 and $5.2M of transaction related expenses, $2.7M of change in fair value of warrant liabilities and $1.4M in restructuring, impairment, site closures and related cost in Q3 21 18

View entire presentation